{"id":"W3004681236","doi":"10.1093/rheumatology/kez684","title":"Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Celgene; Pfizer; Eli Lilly and Company; Amgen","keywords":"Medicine; Ixekizumab; Placebo; Internal medicine; Adalimumab; Psoriatic arthritis; Gastroenterology; Psoriasis Area and Severity Index; Psoriasis; Randomized controlled trial; Arthritis; Rheumatoid arthritis; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004518358,0.000891294,0.001581931,0.0001980606,0.000328729,0.0007563172,0.0006670019,0.0007595728,0.002280795],"category_scores_gemma":[0.001602952,0.000308506,0.001711877,0.0002718833,0.0004961771,0.0006417111,0.0003997108,0.001986271,0.0004437256],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004753083,"about_ca_system_score_gemma":0.001042044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004904734,"about_ca_topic_score_gemma":0.0008525078,"domain_scores_codex":[0.9992766,0.000420888,0.00005114865,0.00008585824,0.00007917164,0.00008631817],"domain_scores_gemma":[0.9985306,0.000296718,0.0004290272,0.0001390432,0.00009448065,0.000510042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8502462,0.02992124,0.01644837,0.0009334907,0.002600779,0.0001604444,0.0002264444,0.0015599,0.01217476,0.0000994907,0.002889783,0.08273914],"study_design_scores_gemma":[0.6790664,0.2759508,0.03910496,0.00007730627,0.001349919,0.0002332778,0.00005222669,0.000988044,0.001542676,0.0001294067,0.001475516,0.00002941693],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947131,0.002611019,0.0003926089,0.0002506833,0.00006138473,0.0006505234,0.000599318,0.00005683292,0.0006643576],"genre_scores_gemma":[0.9909725,0.001992621,0.001605203,0.0007319959,0.0001777415,0.0008818326,0.002528649,0.0000182771,0.00109125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004518358,"threshold_uncertainty_score":0.02389568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05389112942474778,"score_gpt":0.3352843259913323,"score_spread":0.2813931965665846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}